NCT04159766View on ClinicalTrials.gov

A Study With NLY01 in Subjects With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 16, 2019

Primary Completion Date

December 4, 2020

Study Completion Date

December 4, 2020

Conditions
Type2 DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

NLY01

NLY01, a PEGylated form of the anti-diabetic peptide exenatide

DRUG

Placebo

normal saline

Trial Locations (2)

D-41460

Profil Institute fur Stoffwechselforschung GmbH, Neuss

Profil Institute, Neuss

Sponsors

Lead Sponsor

Neuraly, Inc.
All Listed Sponsors
lead

Neuraly, Inc.

INDUSTRY

NCT04159766 - A Study With NLY01 in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter